Fotis Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 29-12-2024
- Paid Up Capital ₹ 1.95 M
as on 29-12-2024
- Company Age 12 Year, 20 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.04 Cr
as on 29-12-2024
- Revenue 7.98%
(FY 2020)
- Profit 9.79%
(FY 2020)
- Ebitda 8.96%
(FY 2020)
- Net Worth 15.93%
(FY 2020)
- Total Assets 46.52%
(FY 2020)
About Fotis Lifesciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 1.95 M.
The company currently has active open charges totaling ₹1.04 Cr.
Valiyaparambil Binesh, Jeevakumar Narayanan, and Rajeev Purakkal serve as directors at the Company.
- CIN/LLPIN
U24230KL2012PTC033028
- Company No.
033028
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Dec 2012
- Date of AGM
06 Nov 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Ernakulam, Kerala, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Fotis Lifesciences?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Valiyaparambil Binesh  | Managing Director | 28-Dec-2012 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Jeevakumar Narayanan | Director | 28-Dec-2012 | Current |
| Rajeev Purakkal | Director | 28-Dec-2012 | Current |
Financial Performance of Fotis Lifesciences.
Fotis Lifesciences Private Limited, for the financial year ended 2020, experienced modest growth in revenue, with a 7.98% increase. The company also saw a slight improvement in profitability, with a 9.79% increase in profit. The company's net worth Soared by an impressive increase of 15.93%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Fotis Lifesciences?
In 2020, Fotis Lifesciences had a promoter holding of 97.44% and a public holding of 2.56%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 11 Jan 2024 | ₹7.88 M | Open |
State Bank Of India Creation Date: 18 Oct 2019 | ₹2.50 M | Open |
How Many Employees Work at Fotis Lifesciences?
Fotis Lifesciences has a workforce of 17 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Fotis Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Fotis Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
